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which translate into biases and variance in the uptake 
measurement. Moreover, the tracer has typically a source-to-
background ratio that decreases during treatment (e.g. after 
3 weeks for FDG). This intrinsically limits the number of 
interpretable images that can be acquired during treatment. 
ii) Dose blurring due to treatment fractionation. Daily setup 
introduces geometrical errors. Random errors blur the 
planned dose, while systematic ones shift it. A systematic 
drift can also be caused patient evolution (tumor regression, 
weight loss), thus making adaptive radiotherapy a desirable 
prerequisite for DP. All this shows that DP must cope with 
limited information about the real uptake heterogeneities. If 
directly converted into a dose prescription, these blurred 
heterogeneities are likely to be further smoothed or even 
shifted by random and systematic errors if the delivered dose 
is considered. While dose blurring is beneficial to uniformity 
within the targets in usual treatment plans, it is actually 
detrimental to any form of intended heterogeneity. Dose 
blurring cannot be compensated for with usual safety 
margins, since they rely on a model that implicitly assumes 
dose uniformity and further reinforces it to guarantee 
coverage. Instead, robust plan optimization must be used, 
either by modeling the setup errors in the optimizer or by 
providing a modified prescription, dilated for systematic 
errors and deconvolved for random errors. It is however 
noteworthy that ensuring coverage might sound paradoxical 
in DP: it widens the dose peaks and increases the mean dose, 
whereas DP precisely aims at a selective and parsimonious 
escalation.  
 
Conclusions: Advanced treatment techniques such as 
intensity-modulated radiotherapy make DP technically 
feasible: a non-uniform dose prescription, with rather sharp 
gradients, can be accurately delivered at each fraction. 
Issues are located upstream (poor quality of PET images, 
which further decreases during treatment) and downstream 
(dose blurring due to setup errors and patient evolution). 
These issues lead to delivered doses that are weakly 
correlated to the underlying microscopic reality. To increase 
this correlation, an adaptive treatment strategy is a 
prerequisite to DP. Combined with other confounding factors, 
this weak correlation also jeopardizes the chances for an 
evidence-based approach to succeed in differentiating 
various flavors of DP from each other or from other 
comparable escalation strategies. 
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Since 2012 the Advisory committee for radiation oncology 
practice  ACROP has taken over the responsibility for the 
initiation and coordination of ESTRO internal guidelines ae 
well as multidisciplinary guidelines together with other 
scientific societies. 
During the ESTRO 35 ACROP session C Belka will present the 
workflow and SOP of ACROP, K Tanderup will give an brief 
overview of the ongoing and mature guidelines in the areas 
brachtherapy and physics and Max Niyazi will present the new 
guideline on Target volume delineation in Glioblastoma. 
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The ACROP committee has been established to generate 
European guidelines on radiotherapeutic topics and 
therefore, a group of thirteen experts had been selected to 
draft target delineation guidelines on glioblastoma. This talk 
will summarize the different steps that were taken to pull 
together all relevant information and will highlight the most 
relevant issues having been included within this guideline. In 
brief, treatment preparation, imaging prerequisites, 
delineation guidelines and pitfalls, planning objectives and 
normal tissue constraints will be discussed. The panel 
members have ensured to update this guidline within a 2 
year's time frame and updates will be given as amendments if 
there are scientific breakthroughs. 
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GEC ESTRO has a long term tradition for development and 
publication of guidelines within brachytherapy. These 
initiatives have grown out of working groups, which have a 
structure for joint multicenter research and development 
projects. The working groups have facilitated substantial 
progress within e.g. imaging, target definition and treatment 
planning, and this has become the basis of novel guidelines 
such as the GEC ESTRO recommendations for cervix, 
prostate, breast, as well as head & neck brachytherapy. The 
most recent example is the guideline on target definition for 
accelerated partial breast irradiation (APBI) which was 
published by the GEC ESTRO breast working group (Strnad et 
al) in June 2015 in Radiotherapy & Oncology. In parallel, the 
GEC ESTRO breast working group has been carrying out a 
randomized study on APBI, and this has further strengthened 
the impact of the guidelines. The clinical outcome of the 
study was published in Lancet in October 2015, and this is an 
excellent example of possible synergy between development 
of guidelines and related research activities. Other initiatives 
from GEC ESTRO include the current development of 
guidelines on bladder brachytherapy (Bradley Pieters), 
quality assurance of ultrasound in brachytherapy (Frank 
André-Siebert), as well as an update on head & neck 
brachytherapy (György Kovács). During the last decade there 
has been extensive collaboration between ESTRO (in 
particular the BRAPHYQS working group and AAPM therapy 
group on joint physics recommendations and guidelines. The 
underlying idea is that the gathering of experts from 
different continents improves quality, and that 
geographically broader views improve the global applicability 
of guidelines. Examples of recently published joint GEC 
ESTRO/AAPM guidelines are guidelines for uncertainty 
analysis (Christian Kirisits), robotic brachytherapy (Tarun 
Podder), and the report on High Energy Brachytherapy 
Dosimetry (Jose Perez-Calatayud). Uncertainty analysis is an 
example of a research field which has been well developed in 
external beam radiotherapy, but was less developed in 
brachytherapy for many years – mainly due to the fact that 
3D imaging was introduced later in brachytherapy than in 
external beam radiotherapy. The guidelines for uncertainty 
analysis (Kirisits) showed therefore big impact on the field, 
and there is altogether now an increasing attention towards 
quantification of uncertainties in brachytherapy and 
considerations about how to improve clinical outcome by 
decreasing uncertainties. Joint GEC ESTRO/AAPM 
recommendations currently in progress are: TG - 167 
Recommendations by the AAPM and GEC-ESTRO on the use of 
new or innovative brachytherapy sources, devices, 
applicators, or applications: Report of Task Group 167 
(Ravinder Nath) and Supplement 2 to the 2004 update of the 
AAPM Task Group No. 43 Report (Mark Rivard). ESTRO physics 
has published several booklets on QA guidelines. Non-
brachytherapy physics guidelines in progress are Quality 
Management in RT: The use of industry Quality Tools (Crister 
Ceberg), QA guidelines for CBCT developed together with 
EFOMP (Alberto Torressin), and also guidelines on Technology 
for Precision Small Animal Radiotherapy Research (Frank 
Verhaegen and Dietmar Georg). ESTRO physics committee 
and AAPM are currently working on a memorandum of 
understanding (MoU) with the aim of increasing scientific 
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interactions and strategic relationships between the 
societies. The MoU will facilitate collaboration across the 
ocean on e.g. Joint Task Groups, Scientific meetings and 
Education. The development of reports (e.g. AAPM task group 
reports, professional guidelines, etc.) should seek 
collaboration between the two societies where appropriate 
and feasible. Such collaboration could be achieved by inviting 
joint membership on appropriate drafting task groups by the 
initiating society. Both societies have now Standard 
Operating Procedures (SOP) available for development of 
guidelines, which gives a good structure for initiating 
international guidelines and securing high quality reviews - 
representing both Europe and North America – in upcoming 
guidelines. 
 
Proffered Papers: Radiobiology 5: Imaging and molecular 
biomarkers in radiation oncology  
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Freiburg, Germany 
 
Purpose or Objective: There is increasing evidence that 
antibodies blocking the PD-1 checkpoint (either anti-PD-1 or 
anti-PD-L1) dramatically increase in-field anti-tumor 
responses to ionizing radiation and enhance abscopal effects 
on non-irradiated metastases. Here, we developed PET 
tracers based on therapeutic surrogate antibodies that 
enable to non-invasively visualize not only the PD-1 and PD-
L1 expression in mice but also the biodistribution of the 
surrogate checkpoint-blocking antibodies. 
 
Material and Methods: Two novel PET tracers were 
developed by conjugation of anti-murine PD-1 and PD-L1 
surrogate checkpoint-blocking antibodies with the chelator 
NOTA and labeling with the radioisotope 64Cu. Non-invasive 
PET imaging was performed on naïve and tumor-bearing 
mice. Mice bearing s.c. B16 melanomas were treated with 
hypofractionated radiation therapy (hRT) using two fractions 
of 12 Gy in combination with CTLA-4 checkpoint blockade 
several days before PET imaging. PD-1 or PD-L1 knockout 
mice and PD-L1-deficient B16 cells generated using the 
CRISPR/Cas technology served as specificity controls. 
 
Results: The newly developed PD-1 and PD-L1 PET tracers 
allowed the highly specific and high-resolution imaging of PD-
1 and PD-L1 expression and of the biodistribution of the two 
therapeutic antibodies in both naïve and tumor-bearing mice 
treated with hRT and CTLA-4 checkpoint blockade. Imaging 
of the respective knockout mice, blocking experiments with 
an excess amount of unlabeled antibodies, and the analysis of 
animals bearing both wild-type B16 melanomas and PD-L1-
CRISPR knockout melanomas demonstrated the high 
specificity of the two newly developed PET tracers. The in 
vivo imaging data were confirmed by ex vivo biodistribution 
analyses. The targets of the PET tracer antibodies were 
verified by ex vivo flow cytometric analyses of tumor single-
cell suspensions and cell suspensions of secondary lymphoid 
and other organs. Interestingly, visualization of immune-
related adverse events was also possible. 
 
Conclusion: We developed two innovative PET tracers that 
allow imaging the expression of the receptor/ligand pair of 
the important PD-1 checkpoint and the biodistribution of 
surrogate checkpoint-blocking antibodies in fully 
immunocompetent mice. This technology also enabled whole-
body pictures of combination radio/immunotherapies. 
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Purpose or Objective: Objectives: Aerobic glycolysis is the 
main pathway of energy production in tumors (Warburg 
effect), and ionizing radiation is reported to switch this to 
mitochondrial oxidative phosphorylation. We developed a 
novel PET probe,18F-2-tert-butyl-4-chloro-5- {6-[2-(2-fluoro-
ethoxy)-ethoxy]-pyridin-3-ylmethoxy}-2H-pyridazin-3-one 
(18F-BCPP-EF), for imaging mitochondrial complex I (MC-I) 
activity. In this study, early detection of tumor 
radiotherapeutic effect was evaluated using 18F-BCPP-EF and 
compared with 18F-FDG and apoptosis index. 
 
Material and Methods: Methods: Tumor uptake of 18F-BCPP-
EF or 18F-FDG was examined in C3H/HeN mice inoculated 
with murine squamous cell carcinoma SCCVII after a single 
dose of x-ray irradiation, 0, 6, 15, or 30 Gy. Apoptosis 
incidence was determined by TUNEL staining in excised tumor 
tissue. 
 
Results: Results: Tumor growth suppression was dose-
dependent; tumor grew 10 fold (0 Gy), 5 fold (6 Gy), 2 fold 
(15 Gy), and reduced to half in its volume (30 Gy) 14 days 
after treatment. 18F-BCPP-EF uptake was significantly 
increased as early as 2 days (15 Gy) or 3 days (30 Gy) after 
irradiation, at time points when tumor size or apoptosis index 
showed no difference among radiation doses. In contrast, 
18F-FDG uptake was initially increased dose-dependently, 
remained elevated, and eventually decreased 10 days after 
30 Gy when tumor size was already reduced. Apoptosis index 
was increased after irradiation but failed to correlate with 
tumor response. The uptakes of 18F-BCPP-EF and 18F-FDG, as 
well as AI, were plotted against Tvol on day 14 as surrogate 
of radiotherapeutic effect. Highly significant negative 
correlations were observed between the uptake of 18F-BCPP-
EF and Tvol on day 14, as early as on day 2, and on each day 
up to day 7, and in all days combined. In contrast, between 
tumor uptake of 18F-FDG and Tvol on day 14, there was a 
significant negative correlation on day 2 and positive 
correlations on day 10 and on day 14, with no correlation in 
all days combined. 
 
Conclusion: Conclusion: Tumor uptake of 18F-BCPP-EF was 
increased dose-dependently early after irradiation when 18F-
FDG uptake and apoptosis index remained elevated 
regardless of radiation doses or its efficacy. The results 
suggest that 18F-BCPP-EF is a promising “positive” MC-I 
imaging PET probe for early detection of adequacy of tumor 
radiotherapy.  
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Purpose or Objective: PET imaging studies with the hypoxia 
tracer 18F-MISO typically show a heterogeneous distribution 
within the tumour, and regions of high uptake have been 
proposed as targets for dose painting. However, there is no 
widely-accepted method to determine dose prescriptions 
from hypoxia imaging. Oxygen diffusion distances in tissue 
(~100 μm) are smaller than the PET resolution (~4 mm) so a 
range of radiosensitivities may exist within each voxel. 
Furthermore, the perfused vasculature is not constant over 
